Supported by the International Atomic Energy Agency (IAEA) in a multicenter worldwide trial with low-, intermediate-, and high-income countries, this study aimed to characterize the extent of PCa (local, nodal, and metastatic involvement) using 68Ga-PSMA-11 PET/CT; compare the diagnostic performance of 68Ga-PSMA-11 PET/CT and MRI, using as a gold standard the radical prostatectomy histopathology findings; and assess the impact of 68Ga-PSMA-11 PET/CT on treatment decision-making, specifically changes in surgical indication. The gene discussed is FOLH1; the disease is posterior cortical atrophy.